Explore Business Standard
Dengue Cases
Forty-six new dengue cases have been reported from Kailasahar town of Tripura's Unakoti district, an official said. Thirteen out of the 46 patients are currently undergoing treatment in hospitals, the official said. Dr Rohan Paul of Kailasahar Sub-Divisional Hospital said, "The situation in Kailasahar is well under control. There is no cause for panic." He said Kailasahar town is more prone to dengue than other areas of the state as tests for the mosquito-borne disease are conducted year-round. He expressed concern that many individuals resort to self-medication without proper medical consultation. "We are suggesting people to undergo dengue tests at the sub-divisional hospital or at nearby primary health centres. Taking medicine without proper diagnosis can lead to health risks," Paul said. He said that dengue is transmitted by Aedes mosquito, which breeds in stagnant water. "People should ensure there is no waterlogging around their homes or workplaces to prevent mosquito ...
Delhi registered a record high number of Chikungunya and Malaria cases in the past five years, while dengue cases declined, according to official data. As of November 9 this year, 728 malaria cases and 172 chikungunya cases were reported in the city. In 2020, there were 228 malaria cases, in 2021, 167 cases, in 2022, 263 cases, and in 2023, 426 cases. The tally includes 19 cases reported in the week leading up to November 9, according to the Municipal Corporation of Delhi's weekly report on mosquito-borne diseases. The number of chikungunya cases in 2020 stood at 111, in 2021, there were 89 cases, in 2022, 48 cases, and in 2023, 65 cases. This year, as of November 9, the number of chikungunya cases was 172. Meanwhile, 4,533 dengue cases were reported in Delhi in 2024, including 472 cases in November. In comparison, there were 9,266 dengue cases reported in 2023. The number of dengue cases has sharply declined since last month, when it doubled to 2,431 cases from 1,052 cases in
Intensified and coordinated efforts in controlling the dengue virus helped to substantially reduce the mortality and spread of the vector borne disease in the state, the Tamil Nadu Health Department said on Friday. Amid the ongoing North East Monsoon, Tamil Nadu has been reporting sporadic cases of fever and dengue across the state. Following this, the Health and Family Welfare Department has intensified monitoring and surveillance efforts to contain the spread of dengue. "From January till November 5, 20,138 dengue cases have been reported in Tamil Nadu, with affected individuals recovering successfully. Unfortunately, 8 people lost their lives due to delay in seeking appropriate medical care," a release here said. Among the deceased was a six-year-old girl from Chengalpattu district. Strict interventions were in place to prevent dengue outbreaks and further reduce dengue-related fatalities, the release said. The intensified efforts have led to a reduction in cases over the previo
The ICMR and Panacea Biotec have initiated the first-ever phase three clinical trial for developing a dengue vaccine in India, the Union Health Ministry said on Wednesday. India's indigenous tetravalent dengue vaccine, DengiAll, has been developed by Panacea Biotec and the first participant in this trial was vaccinated on Wednesday at the Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak. The phase three clinical trial will be conducted across 19 sites in 18 states and union territories, involving more than 10,335 healthy adult participants. "The initiation of this phase three clinical trial for India's first indigenous dengue vaccine marks a critical advancement in our fight against dengue. It reflects our commitment to protecting our citizens from this pervasive disease and underscores India's capabilities in vaccine research and development," Union Health Minister J P Nadda said. "Through this collaboration between ICMR and Panacea Biotec, we are no
The number of dengue cases in West Bengal is rising, as around 500 people, mostly in rural areas, were down with the mosquito-borne viral disease in the last week of July, a health department official said on Thursday. The official, however, said that the situation is under control. Since January, at least 2,640 people have been diagnosed with the disease in the state, with North 24 Parganas district topping the chart with 363 cases. Between July 24 and 31, West Bengal reported around 500 dengue cases, with 68 from Murshidabad district and 50 from North 24 Parganas. "There has been a rise in dengue cases since the last week of July. This is mainly due to the monsoon. We see such a spike in dengue cases almost every year at this time. There is nothing to worry about. The situation is under control," the official told PTI. During the final week in July, Malda district reported 53 dengue cases, followed by Hooghly (50), Purba Bardhaman (44) and South 24 Parganas (32). Eighteen cases
Mumbai has recorded a "slight increase" in malaria and H1N1 (flu) cases in July 2024 at 797 and 161, respectively, as compared to the same month last year, the city civic body said on Wednesday. In its report on "Monsoon-related diseases", the Brihanmumbai Municipal Corporation (BMC) said as compared to July 2023, the data for July 2024 showed a decline in cases of dengue, leptospirosis and gastroenteritis, but a slight uptick in malaria and H1N1 (flu) infections in the financial capital. Mumbai reported 797 cases of malaria and 161 of H1N1 in July 2024, up from 721 and 106, respectively, in the same month last year, according to the report. Cases of dengue, leptospirosis, gastroenteritis, hepatitis and chikungunya dropped to 535, 141, 1239, 146 and 25 in July 2024 from 685, 413, 1767, 144 and 27 in July 2023, respectively, it said. The BMC said it covered nearly 11.95 lakh households and about 55.80 lakh population during its house-to-house fever survey in July 2024 and gave ...
U.S. health officials on Tuesday warned doctors to be alert for dengue cases as the tropical disease breaks international records. The virus, which is spread by mosquitoes, has been surging worldwide, helped by climate change. In barely six months, countries in the Americas have already broken calendar-year records for dengue cases. The World Health Organization declared an emergency in December, and Puerto Rico declared a public health emergency in March. Dengue remains less common in the continental United States, but in the 50 states so far this year there have been three times more cases than at the same point last year. Most were infections that travelers got abroad, and officials note there is no evidence of a current outbreak. But they also warn that local mosquitos pose a threat. In its health alert Tuesday, the Centers for Disease Control and Prevention advised doctors to know the symptoms, ask questions about where patients recently traveled and consider ordering dengue .
The first bout of dengue can be as life-threatening as the subsequent ones, according to a study which challenges the widely held belief that the viral disease is severe only in secondary infections. The research, published recently in the journal Nature Medicine, analysed severe dengue cases in a group of children in India, showing that more than half could be attributed to primary rather than secondary infection. Over the past two decades, dengue infections have greatly increased in India and the country has one of the largest number of cases globally. Dengue patients fall into two categories -- those experiencing the infection for the first time, known as primary infections and those who get re-infected after a previous exposure, known as secondary infections. The prevailing belief has been that only secondary infections pose significant risks, leading much of the research into vaccine development and treatment to focus on this group. An international team led by researchers at
Japanese drug firm Takeda on Tuesday said it has tied up with Hyderabad-based firm Biological E Ltd to manufacture its dengue vaccine. The partnership marks a crucial step in the fight against the global public health threat of dengue fever, aligning with the disease-specific target set by the World Health Organisation to achieve zero case-fatality rate due to dengue by 2030, the company said in a statement. The partnership will substantially enhance manufacturing capabilities to ensure a sustainable global supply of the vaccine, it added. Biological E will scale up its production capacity to potentially reach 50 million doses annually, accelerating Takeda's efforts to manufacture 100 million doses annually within the decade, it said. "We are proud to announce a strategic manufacturing partnership with Biological E Ltd which has deep expertise in vaccine manufacturing and longstanding support of public health programmes around the world," Takeda President of the Global Vaccine ...